NEW CITI Course: COVID-19: Back to Campus
AAMC and CITI Program have partnered to launch a complimentary course for staff, students, and faculty on safely
returning to research activities on campus. This course is strictly voluntary for those wishing to have additional information
about how to maintain a safe research environment in the time of COVID-19. This course was designed by AAMC and
CITI and does not necessarily follow all of OUHSC guidelines for return to work or return to research (which can be found
here: https://research.ouhsc.edu/Resources/COVID-Research-Updates). Please be certain to review OUHSC policies if
you have any questions. For additional information see the attached document.
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/CITI COVID.docx?ver=2020-06-29-072637-950
The FY20 Defense Established Program to Stimulate Competitive Research (DEPSCoR) funding opportunity
has been announced! The announcement, along with extra details provided by Oklahoma EPSCoR State Director Dr. Jerry
Malayer, is attached. Please take special note of the webinar scheduled for July 21st at 1:00 PM (EDT). Related PDF
documents are attached.
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/DEPSCOR - FOA-AFRL-AFOSR-2020-0004_Amendment 1_Published 22 MAY 2020.pdf?ver=2020-06-29-072637-967
NIH is offering the 2020 NIH VIRTUAL SUMMER ENRICHMENT PROGRAM. It is open to all students from high
school to graduate/professional school, and would be a terrific way to engage students around science. The program offers
a number of online resources for career and professional development throughout the summer. For more complete information
go to: https://www.training.nih.gov/2020_nih_virtual_summer_enrichment_program
REMINDER of SoonerTrack Update: Due to the ongoing PeopleSoft implementation, SoonerTrack will be down from 5 pm
on Tuesday the 30th to noon on Wednesday the 1st.
A Walk-Through of the PHS Human Subjects and Clinical Trials Information Form
PHS has updated their video to align with the latest form update (FORMS-F).
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/Transition to FORMS-F 5-13-2020.pdf?ver=2020-06-01-083255-460
OMB M-20-26: Extension of Administrative Relief for Recipients and Applicants of Federal Financial Assistance
(COVID-19) - a memo was published by OMB, extending certain of the flexibilities provided by M-20-17.
NIH WILL ACCEPT PRELIMINARY DATA AS POST-SUBMISSION MATERIAL AND OTHER COVID-19 RELATED APPLICATION FLeXIBILITIES:
Oklahoma Covid-19 Working Group
Information on research activities in Oklahoma that address the Covid-19 pandemic has been added to the OCTSI Website
(http://octsi.ouhsc.edu/covid-19%20working%20group ) A list of investigators in the working group and their planned or ongoing projects
are described. A list of funded Covid-19 Seed Projects at OUHSC and OU Norman is also included. To be added to the Oklahoma
Covid-19 Working Group or to have your information updated, please contact: Mark L. Lang PhD, Presbyterian Health Foundation
Presidential Professor, Department of Microbiology and Immunology, OUHSC ( firstname.lastname@example.org ).
Oklahoma Shared Clinical and Translational Resources Clinical and Translational Research Pilot (CTRP) Grants
The purpose of the program is to provide funding for collaborative and/or multi-disciplinary clinical and translational pilot projects
between investigators of the OSCTR member institutions. The program seeks to support proposals designed to generate preliminary
data that will result in improved health and/or healthcare for citizens of Oklahoma and other IDeA states and enhance the competitiveness
of the investigators for future extramural funding. The program also seeks to fund innovative concepts, approaches, and methodologies
that bring fresh new ideas to solving the health issues of those living in Oklahoma and collaborating IDeA states. Projects that focus on
the medically underserved and on health concerns prevalent within Oklahoma and our OSCTR partners will be a priority. Only projects
which meet the NIH definition of clinical and/or translational research will be accepted.
Approved CTRP grants will be funded for a period starting January 1, 2021 contingent on NIH approval of just in time (JIT) information.
All funds are required to be expended by December 31, 2021.
The forms, instructions, and submission link can be found at: http://osctr.ouhsc.edu/pilots2020
Deadlines for submission: Pilot Proposal – Friday, August 7, 2020 at 5:00 PM CDT
Oklahoma Shared Clinical and Translational Resources Community-Engaged Research Exploratory (CERE) Awards
This program is intended to support community engagement to develop funded research partnerships. Funds can be used for research
development activities, including convening partners, working with individuals pursuing related work, and conducting needs assessments
in community settings. The funds cannot be used to support actual human-subjects research protocols, which can be funded under other
OSCTR pilot research programs and/or external funding.
The application should consist of a 2-page letter from the main applicant (which can be either a community agency or an academic
researcher) describing the collaboration, the contributions that the proposed work will make to a successful research partnership, and
a line item budget. Budget requests are expected to be $5,000-$10,000 with budgets that permit the expenditure of the entire award by
June 30, 2021. A separate letter of support from either the academic or community partner indicating their agreement with the proposed
activities should also be included. Proposals will be evaluated on a rolling basis beginning July 1, 2020. Please submit proposals by email
Interested applicants can discuss their proposal, eligibility, allowable budget items, and available funding by contacting the OSCTR staff
at email@example.com or call 405-271-3480.
OU Office of Technology Commercialization presents a new opportunity to engage with industry (email firstname.lastname@example.org or
email@example.com for specific submission details):
Astellas Pharma is looking to engage with academia for developing novel early-stage small molecule compounds having potential to cure
disease (OUT OF SCOPE: cancer, infectious disease, metabolic disease, CNS disease, rare diseases). Non-confidential summary
application (~template available~) due July 20th, 2020.
- Significant in vivo efficacy that can reverse pathophysiology
- Drug-like properties
- Higher activity in target cell
- Higher target specificity
- Clarified direct target binding and/or modification
For additional information, go to: http://www.ou.edu/otc/ICO
The OU Medicine Laboratory is looking for equipment to assist with their COVID-19 testing.
Please see the attached list of equipment needs. Please reply to VPR@ouhsc.edu if you have any of this equipment
you could possibly loan. URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/Testing Donations.xlsx?ver=2020-06-01-083249-427
DONATION OF TESTING SUPPLIES
OU Physicians has requested that researchers look into their supplies and see whether they can donate any of the
Testing supplies listed in the attached “Testing Donations”. Please return the complete form to Kristen.Namey@oumedicine.com.
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/Testing Donations.xlsx?ver=2020-06-01-083249-427
DONATION OF PPE SUPPLIES
OU Physicians has requested that researchers look into their supplies and see whether they can donate any of the
PPE supplies listed in the attached “research PPE donation”. The first line is an example of how to fill out the form.
Please return completed form to Erin-Bailey@ouhsc.edu.
URL: https://research.ouhsc.edu/Portals/1329/Assets/Documents/COVID Ramp Up Ask List.docx?ver=2020-06-01-083246-413
Up to date information on allowable OUHSC research activity in response to COVID-19 can be found at:
Fast-Grants – Fast Funding for COVID-19 Science
NIH has created a central site for its current COVID-19 guidance at
OUHSC Financial Administrators:
The federal and state governments are asking that all institutions track their expenditures related to the
COVID-19 pandemic. It is imperative that everyone is diligent in tracking all COVID-19 related expenditures for future
reimbursement opportunities. Effective immediately, all COVID-19-related expenditures incurred since March 12 should be
coded to a newly created COVID subclass. These expenditures include, but are not limited to direct COVID-19 costs,
increased housekeeping and maintenance costs, expenditures related to business process modifications, preparatory actions,
daily operations, and communications resulting from COVID-19. If COVID related expenses, since March 12, have already
been paid, please process a cost transfer using the new COVID subclass. Research faculty and staff should also track their
expenditures incurred by the shutdown of their projects and laboratories including the loss of samples, reagents, animals and
other items. Also, keep in mind that, asyou resume your activities in your lab, any expenses required to restart the lab should
be coded with the COVID subclass. This will help significantly when applying for any administrative supplements or other
COVID-19 related relief efforts. Questions regarding the use of the subclass on non-research chartfields should be forwarded to
firstname.lastname@example.org and research related questions can be sent to email@example.com.
OUHSC Funding Requests related to COVID-19 – when submitting an item in the OUHSC SoonerTrack system related to
COVID-19 please include “COVID-19” in the title so that we are able to search on it later.
COVID-19/Coronavirus Resources – a list from InfoEd
Notice of Special Interest (NOSI) Regarding the Availability of Urgent Competitive Revisions for Research on
Coronavirus Disease 2019 (COV-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
Reminder of Upcoming FORMS-F and Inclusion Across the Lifespan Requirements for NIH Applicants and Recipients
Submitting Post-Submission Updates Using the Human Subjects System (HSS)
NIH Summary Statement Available to the Signing Officials (SO) through the eRA Commons
NIAID Late Application Policy for NIAID-Specific FOAs with Due Dates in July and August 2020
Notice of Informational Webinar on the Intramural NIGMS Postdoctoral Research Associate Training (PRAT) Program and Fi2
Application Process (NOT-GM-20-037)
Notice of Information for Date of Submission to NOT-MD-20-019 and NIMHD Consideration for FY Award.
Changes to Handling of Applications Submitted to Program Announcements with Special Receipt, Referral, and/or Review
Considerations (PAR) and Program Announcements with Set-Aside Funds (PAS) (NOT-OD-20-114)
Notice of Pre-Application Webinar for the RADx-UP Initiative (NOT-OD-20-131)
Request for Information (RFI): Enhancing Rigor, Transparency, and Translatability to Improve Biomedical Research Involving
Animal Models (NOT-OD-20-130)
Request for Information: Challenges and Opportunities in Improving our Understanding of Transposable Elements and Somatic
Notice of Change to NIA-Specific Text in RFA-OD-19-029 "The Intersection of Sex and Gender Influences on Health and Disease
(R01 Clinical Trial Optional)" (NOT-AG-20-037)
Notice of NEI's Participation in PA-20-135 "Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement –
Clinical Trial Optional)" (NOT-EY-20-010)
Notice of Change to Target FOA and Expiration Date of NOT-HL-19-678 "Notice of Special Interest (NOSI): Bold New
Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases" (NOT-HL-20-797)
Notice of Intent to Publish a Funding Opportunity Announcement for "BRAIN Initiative Fellows: Ruth L. Kirschstein National
Research Service Award (NRSA) Individual Postdoctoral Fellowship (F32)" (NOT-MH-20-062)
Notice of Specialist Interest (NOSI): Advancing Polycystic Kidney Disease (PKD) Research through Catalytic Tool and
Technology Development (NOT-DK-20-034)
Notice of Special Interest (NOSI) in Research on Risk and Prevention of Black Youth Suicide
Notice of Special Interest (NOSI): Common Fund ALS-related Transformative Research Award
(R01 Clinical Trial Optional) (NOT-RM-20-019)
Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to
Address COVID-19 Public Heath Need (NOT-TR-20-029)
Please Note: When only one application is allowed per Institution according to the sponsor
instructions, a one-page letter of intent summarizing the proposed project should be submitted
to the Vice President for Research at least two months prior to the application deadline (unless
otherwise noted). The letters of intent will be reviewed and a single application will be chosen
for submission from the University.
Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
(PAR-20-212) – Deadline September 7, 2020 and September 7, 2021
HIV/AIDS Scholars Using Nonhuman Primate (NHP) Models Program (K01 Independent Clinical Trial Not Allowed)
(PAR-20-231) – Deadline September 7, 2020 and September 7, 2021
Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)
(PAR-20-232) – Deadline October 16, 2020
Enabling Technologies to Accelerate Development of Oral Biodevices (R01 Clinical Trial Not Allowed)
(PAR-20-233) – Deadline October 5, 2020
NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult
Populations (R01 Clinical Trial Required) (PAR-20-234) – Deadline July 1, 2020 and August 3, 2020
Behavioral Tasks Targeting Brain Systems Relevant to Anhedonia (R01 Basic Experimental Studies with Humans
Required) (PAR-20-235) - Deadline October 5, 2020
Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and
Vulnerable Populations (R01- Clinical Trial Optional) (PAR-20-237)
Deadline August 28, 2020 and December 1, 2020
Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional)
(RFA-AG-21-023) - Deadline November 13, 2020
Martin Delaney Collaboratories for HIV Cure Research (UM1 Clinical Trial Not Allowed)
(RFA-AI-20-035) – Deadline December 7, 2020
Martin Delaney Collaboratory for Pediatric HIV Cure Research (UM1 Clinical Trial Not Allowed)
(RFA-AI-20-036) – Deadline December 7, 2020
Interventions to Prevent Electronic Nicotine Delivery Systems (ENDS) Use Among Adolescents
(R01 - Clinical Trial Optional) (RFA-DA-21-009) – Deadline October 19, 2020
Laboratory, Data Analysis, and Coordinating Center (LDACC) for the Developmental Genotype-Tissue Expression
Project(U24) (Clinical Trial Not Allowed) (RFA-HG-20-039) – Deadline November 13, 2020
Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting
(U01 - Clinical Trials Required) (RFA-HL-21-001) – Deadline December 9, 2020
Regional Medical Libraries for the Network of the National Library of Medicine (UG4)
(RFA-LM-20-001) - Deadline September 11, 2020